According to Future Market Insights’ (FMIs’) most recent revised industry analysis, the global Gamma Probe Devices Market Growth was valued at more than US$ 72.4 Mn in 2020, and is expected to grow at a CAGR of close to 9.5% during the forecast period.
Gamma probe devices help surgeons identify radiolabeled tissue prior to surgery for radioguided analysis, diagnosis, and procedures. Surgeons frequently have difficulty locating tissues within the human body, such as cancers, parathyroid glands, and lymph nodes. As a result, using a gamma probe device correctly allows the medical expert to make a smaller incision while still locating the tissues of interest.
Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-10037
The rising number of thyroid and breast cancer patients, as well as the growing preference for non-invasive procedures due to shorter hospital stays and lower costs, will drive the gamma probe devices market.
Most minimally invasive surgical procedures require gamma probe devices. Gamma probe device innovation and improved patient outcomes in minimally invasive surgical procedures using gamma probe devices are also expected to drive market growth.
The growing preference for image-guided procedures, as well as recent advancements in low-cost gamma probe devices, are expected to boost market growth over the forecast period.
Gamma probe devices are increasingly being used in breast cancer sentinel lymph node mapping and parathyroid surgery. As per WHO, 2.3 million women were diagnosed with cancer of breast while 685 thousand deaths happened due to the same reason in 2020.
According to the Cancer Research UK, breast cancer is the fourth most common cause of cancer death in the UK, accounting for approximately 7% of all cancer deaths. Breast cancer, for example, can be prevented if patients are diagnosed early.
However, till now, only few key players such as Hologic Inc., Danaher, BIODEX, and Southern Scientific Ltd. are actively involved in manufacturing of gamma probe devices, which will create huge opportunities for other small as well as big manufacturers to enter the gamma probe devices market.
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-10037
Key Takeaways from Market Study
- The trolley mounted device segment held the largest share of approximately 1% in 2021, owing to an increase in demand from hospitals due to the convenience factor, i.e. easy operability and lower cost.
- The use of a gamma probe device resulted in a higher SLN detection rate, more accurate SLNB site identification (axillary or extra-axillary sites), and fewer problems, resulting in the application segment accounting for more than 56% of the market.
- The hospitals segment will account for more than 52.8% of the gamma probe devices market in 2021, owing to the increasing demand for gamma probe devices in critical care units for breast and thyroid cancer procedures.
- Europe accounts for the highest share for approximately 43.5% of the global gamma probe devices market share in 2021, due to the increasing breast cancer mortality rate in this region.
“Increasing prevalence of breast cancer and surging awareness among the people about the benefits of gamma radiation in various treatment will boost the market over the forecast period” says an analyst at FMI.
Who is winning?
The gamma probe device market is relatively consolidated. There are several companies in this industry, the most prominent of which are Hologic, LabLogic Group Holdings, and Danaher Corporation. These companies have strong product portfolios, product innovation, and cutting-edge business strategies.
These market leaders have pursued a variety of business strategies, including strategic alliances with other medical device companies for product marketing and services, as well as collaboration with healthcare institutions for advanced technology research and development.
- In August 2020, Hologic announced a collaboration with RadNet towards the development of artificial intelligence tools in breast health.
In December 2019, Mammotome, a subdivision of Danahera Diagnostics, unveiled a new brand identity with an updated look and feel. Mammotome also began distribution of the TruCore TM II automatic core biopsy instrument in various regions.
Why Future Market Insights?
- Comprehensive analysis on evolving purchase pattern across different geographies
- Detailed insights of market segments and sub-segments for historical as well as forecast period
- A competitive analysis of prominent players and emerging players in the keyword market
- Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
Request for Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-10037
Gamma Probe Devices Market by Category
By Modality
- Hand Held Device
- Benchtop Device
- Trolley Mounted Device
By Application
- Thyroid Uptake
- Sentinel Lymph Node Uptake
- Breast Cancer
- Melanoma
- Colon Cancer
- NSCLC
- Renal cancer
- Others
By End-User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs